A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 612 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Nivolumab July 1, 2021 Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and... November 8, 2022 Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... January 7, 2020 One Million Masks Donated! But GreaterGood Will Continue to Help Where... October 5, 2020 Load more HOT NEWS Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce 2026 ESMO TAT Honorary Award Recipient Announced Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and...
